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Poster Session I S225Conclusion:Our results indicate an increased risk of acuteGvHD in
association with DPB1 mismatch regardless of the TCE classifica-
tion. TCE classification did not correlate with any transplant out-
come considered in our cohort. This analysis does not support the
clinical relevance of ranking DPB1 mismatches based on the TCE
algorithm.195
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Treatment options for adults with primary refractory AML
(PREF AML) are extremely limited. Whilst sibling allogeneic
stem cell transplantation can result in long term survival most pa-
tients lack a matched family donor and are destined to die of refrac-
tory disease. Greater availability of unrelated donors and
improvements in supportive care have increased the proportion
of patients with PREFAML in whom allografting is technically fea-
sible but the outcome of unrelated donor transplantation in this
population has not been extensively studied. We therefore analysed
overall survival in 168 patients with PREF AML who underwent
unrelated donor transplantation between 1994 and 2006 with a me-
dian follow-up of 59 months (15-172). 80 patients received three or
more courses of induction chemotherapy. The median percentage
of bone marrow (BM) blasts at transplant was 39%. The 5-year
overall survival for the whole group was 22%. In multivariate anal-
ysis, fewer than three courses of induction chemotherapy, a lower
percentage of BM blasts at transplant and patient CMV seropositiv-
ity were associated with improved survival. We used the prognostic
factors identified in multivariate analysis to develop a scoring sys-
tem. This allowed the delineation of four prognostic groups with
survival rates ranging between 446 11% and 0%. This study dem-
onstrates an important role for unrelated donor transplantation in
the management of selected patients with PREFAML and confirms
the importance of initiating an urgent unrelated donor search in pa-
tients with no matched sibling donor who fail to respond to induc-
tion chemotherapy. Pre-transplant factors allow the identification
of patients with PREF AML who are likely to benefit from unre-
lated donor transplantation.196
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While increasing HLA disparity is known to be associated with
increased risk of significant graft versus host disease (GVHD),
there is less data as to whether increasing HLA disparity is corre-
lated with stronger, clinically significant graft versus leukemia ef-
fects. We examined a group of patients with acute leukemia
undergoing haploidentical HSCT to assess whether 1) there was
a marked difference in relapse rates based on the degree of HLA
mismatch and 2) if early recovery of donor lymphoid subpopula-
tions was associated with less relapse after HLA mismatched
HSCT. Thirty-four adult patients with AML (24) and ALL (10)
underwent haploidentical HSCT between 2005 and 2009 using
a 2 step process which separates the infusion of the lymphoid and
myeloid portions of the graft while attempting to render thelymphocytes tolerant utilizing cyclophosphamide. The patients re-
ceived 2 x10e8/kg donor CD3 cells (DLI) after conditioning with
either TBI 12 Gy (N 5 24) or fludarabine 30 mg/m2  4, thiotepa
5 mg/m2  3, and TBI 2 Gy (N 5 10). Two days after the DLI, all
patients received cyclophosphamide (CY) 60 mg/kg  2 followed
by a CD 34 selected donor product. The TBI based regimen was
given to 80% of patients with ALL and 56% with AML. We exam-
ined relapse rates based on the number of antigen mismatches at A,
B, Cw, and DRB1 in the GVH direction. There were no discern-
able differences based on degree of HLA disparity with even the
most haplodisparate group exhibiting high rates of relapse when
disease was present at HSCT. In contrast, the presence of active
leukemia at the time of HSCT had far more impact on subsequent
relapse rates (see Table).
Table 1. Outcomes Based on Degree of HLA Disparity
4 Antigen 3 Antigen 2 Antigen 1 AntigenMismatch Mismatch Mismatch MismatchNumber of
PatientsRelapsed/
TotalRelapsed/
TotalRelapsed/
TotalRelapsed/
TotalActive Disease
at HSCT17 (50%) 10/12 (83%) 2/2 (100%) 3/3 (100%) N/ACR at HSCT 17 (50%) 3/9 (33%) 1/7 (14%) N/A 0/1 (0%)Total 13/21 (62%) 3/9 (33%) 3/3 (100%) 0/1 (0%)We also examined the impact of immune recovery on relapse. Ab-
solute numbers of NK, and CD4 and CD8 T cells were examined in
the first 4 months post HSCT. T cell, MNC, and total chimerism
was greater than 99% donor-derived at the time of the assessment.
For patients who did or did not relapse post HSCT the median
numbers of lymphoid subsets (cells/uL) were: NK 165 (77-700)
vs 209 (77-660), CD4 105 (18-245) vs 98 (10-403), and CD8 82
(9-1039) vs 176 (2-2380) respectively. In this small series of patients
treated with the 2 step transplant method, relapse was associated
more with the presence of disease at HSCT than with any discern-
able trend in degree of HLA disparity or early immunologic recov-
ery. Other approaches to treat resistant leukemia are required
to substantially improve disease free survival in these high risk
patients.197
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Anti-HLA antibodies (HLA-Ab) predict graft failure in unrelated
donor and single umbilical cord blood (UCB) transplantation. We
measured HLA-Ab in double UCB transplantation (DUCBT) with
the hypothesis that HLA-Ab would predict time to engraftment,
graft failure and UCB unit dominance.
Methods: 73 patients with banked pre-transplant sera who under-
went DUCBT using 4/6 or better allelic HLA-matched UCB
units (2004 -2008) were studied. Labscreen (One Lambda Inc.)
was used to capture class I/II HLA-Ab and the Luminex100 IS
system was used to detect fluorescent tagged binding of human
IgG. Visual software was used to normalize results and to deter-
mine the presence of mixed class I/II HLA-Ab. Positive samples
were tested using single antigen-coated microbeads. Beads with
a 1000 mean fluorescent intensity above baseline were considered
positive. Chimerism was measured using STR typing of informa-
tive alleles. Graft failure was defined as the absence of neutrophil
engraftment 42 days from DUCBT or loss of UCB chimerism by
day 100 without malignant relapse. UCB dominance was defined
as . 90% contribution to hematopoiesis by a single UCB unit at
day 100.
S226 Poster Session IResults: 18 patients withHLA-Ab against UCB unit 1 (9), UCB unit
2 (2) or both UCB units (7) were identified. No differences in cell
doses, viability or baseline characteristics were noted between
patients with/without HLA-Ab. The presence of HLA-Ab was asso-
ciated with an increased risk of graft failure (HLA-Ab against either
UCB unit: OR 8.67, 95%CI 1.89–39.68, p 5 0.0055; HLA-Ab
against both UCB units: OR 16.27, 2.82–93.87, p 5 0.0034). Neu-
trophil engraftment was delayed in the presence of HLA-Ab (median
21 vs. 29 days, p5 0.04) and fewer patients engrafted platelets in the
presence of HLA-Ab (76.4% vs. 50%, p 5 0.03). HLA-Ab against
UCB unit 1 was associated with UCB unit 2 dominance (OR 9.43,
95%CI 1.16–76.47, p 5 0.015), while HLA-Ab against UCB unit
2 was associated with a non-significant trend toward UCB unit 1
dominance (OR 2.70, 95%CI 0.63–12.5, p 5 0.28). Overall survival
was inferior in the presence of HLA-Ab against UCB unit 2 (p 5
0.044) or both UCB units (p5 0.027), but not with HLA-Ab against
UCB unit 1 only.
Conclusions: In DUBCT, the presence of HLA-Ab increases the
risk of graft rejection, prolongs time to engraftment, predicts UCB
dominance and is associated with inferior outcome.HLA-Ab screen-
ing should be incorporated into UCB unit selection strategies in
DUCBT.198
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Through an in vivo zebrafish screen for modulators of hematopoi-
etic stem cell (HSC) development, a small molecule, 16,16-dimethyl
prostaglandin E2 (FT1050) was identified (North, 2007). FT1050
was shown to enhance the engraftment potential of HSCs from mu-
rine bone marrow (mBM) or human umbilical cord blood (hCB) in
murine engraftment models through an increase in proliferation,
survival, migration and homing after a brief (1 to 2 hr) ex vivo treat-
ment (North, 2007; North, 2009; Hoggatt, 2009; North, Goessling,
Zon, unpublished data).We further optimized the ex vivo hCB incu-
bation protocol using whole genome expression arrays and deter-
mined that HSC-containing cell products should be incubated
with 10mMFT1050 for 2 hrs at 37C to obtain the optimal response.
In addition, we observed that FT1050 induces similar gene expres-
sion changes in hBM- and mobilized peripheral blood-derived
CD341 cells. Subsequent functional studies demonstrated that in
keeping with increases of up to 18-fold in CXCR4 gene expression,
cell surface CXCR4 protein expression was also significantly in-
creased. One hour after treatment with10mM FT1050 for 2 hrs at
37C, 4861.9% of CB CD341 cells expressed CXCR4 compared
to 3.560.01% in DMSO control (p\0.05). In vivo CFU-S12 anal-
ysis showed that treatment of mBM cells with 10mM FT1050 for 2
hrs at 37C resulted in greater proliferation with a statistically signif-
icant increase in colony formation, 11.561.4, compared to 460.8
colonies with DMSO control (p\ 0.001). This short-term ex vivo
incubation protocol, 10mM FT1050 for 2 hrs at 37C, has been in-
troduced into an ongoing Phase Ib clinical trial in adults with hema-
tologic malignancies receiving a nonmyeloablative conditioning
(melphalan, fludarabine and ATG) followed by double hCB trans-
plantation, in which one of the two hCBs is incubated with
FT1050 prior to infusion. The primary objective of the study is to
determine the safety of FT1050 treatment of hCB. Preliminary
data demonstrate that this ex vivo incubation can be reliably per-
formed at the clinical site on the day of infusion with good cell recov-
ery and viability. 11 subjects with a median age of 44 years have been
accrued to date, of which two have been treated using the optimized
ex vivo incubation protocol. 10 of 11 patients have achieved an ANC
. 500 beforeDay 42. Transplant relatedmortality has been lowwithone death at Day 53 from respiratory failure. 9 patients are alive, of
which 7 are disease-free. Accrual is ongoing.199
ALLOGENEIC TRANSPLANTATION USING HAPLOIDENTICAL DONOR VER-
SUS UNRELATED CORD BLOOD DONOR: A SINGLE CENTER RETROSPEC-
TIVE STUDY
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We have performed a retrospective comparison of pediatric pa-
tients with leukemia receiving a haplo transplant (n 5 29) or
UCBT (n 5 38) in Ni~no Jesus Children’s Hospital since 1996 to
2010. There were not significant differences in immunophenotype,
disease status and antecedent of prior autograft. However, haplo re-
cipients tended to be older and of male gender.
Engraftment failure was significantly higher following UCBT
965% compared to 765% in haplo transplants (p5 0.001). Median
neutrophil engraftment were at 13 days for haplo and 20 days for
UCBT (p 5 0.01) and platelet engraftment at 11 days for haplo
and 56 days for UCBT (p 5 0.0001). Supportive care (transfusions,
antibiotics, parenteral nutrition and hospitalization days) were sig-
nificantly higher for cord blood transplants.
TRM and acute GVHD (more than grade II) incidence was higher
in UCBT compared to haplo transplants. There were not significant
differences in chronic GVHD and relapse probability between the
two groups. Results are summarized in table 1.
Disease-free survival (DFS) with a median follow-up of 16 months
(range: 1-42) and 57 months (range: 1-150) were of 44610% and
3267% (p 5 0.03) for haplo transplants and UCBT respectively.
When we analyzed AML, there were not differences in DFS with
both type of donor (p 5 0.6). However, DFS for ALL was better
with haplo (41613%) against cord blood (266 9%) (p 5 0.03). Ac-
cording to phase of disease, DFS was similar in early phase (p5 0.7),
but in advanced phase outcomewas better with haplo (37614%) ver-
sus cord blood (2168%) (p 5 0.05).
Multivariate analysis of DFS showed that the main prognostic fac-
tors were disease status at transplant (HR 2.49, p 5 0.02), chronic
GVHD (HR 0.21, p 5 0.0001) and source of stem cells (HR 5.75,
p 5 0.001).
In conclusion, our data suggest that haploidentical donor is a good
alternative for patients lacking an HLA identical donor.
Table 1. Results.
aGVHD >II TRM Relapse DFSHaplo (n529) 19±7% 25±9% 48±12% 44±10%
UCB (n538) 44±10% 57±9% 25±9% 32±7%
P 0.03 0.05 0.7 0.03200
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Background: CD341 stem cell selection depletes T cells responsi-
ble for severe aGVHD (Lang et al., Blood, 2003). CD341 selected
grafts have been associated with delayed IR (Ball et al, BMT, 2005,
Eyrich et al, BJH, 2001). Delayed IR is a significant risk factor for
